Australia markets open in 47 minutes

    -37.40 (-0.49%)

    +0.0017 (+0.24%)
  • ASX 200

    -39.50 (-0.54%)
  • OIL

    +1.91 (+2.80%)
  • GOLD

    -2.60 (-0.15%)

    +2,190.15 (+2.75%)
  • CMC Crypto 200

    +31.88 (+2.23%)

SHAREHOLDER ALERT: Robbins LLP Announces that Amarin Corporation plc (AMRN) is Being Sued for Misleading Shareholders

  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

SAN DIEGO, Calif., October 28, 2021--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP announces that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Amarin Corporation plc (NASDAQ: AMRN) securities between December 5, 2018 and June 21, 2021, for violations of the Securities Exchange Act of 1934. Amarin is a biopharmaceutical company whose lead product since 2008 is Vascepa®.

If you suffered a loss due to Amarin Corporation plc's misconduct, click here.

Amarin Corporation plc (AMNR) Misled the Investing Public Regarding the Impact Pending Patent Litigation Would Have on the Company's Future Prospects

According to the complaint, to protect its market share, Amarin obtained dozens of U.S. patents in connection with Vascepa, including for its formulation and method of use. Notwithstanding, Amarin was engaged in patent litigation against applicants who submitted Abbreviated New Drug Applications ("ANDA") for generic drug products of Vascepa. During the relevant period, defendants gave the impression that such litigation was a cost of doing business and did not pose a real threat to the Company's business or future prospects. Specifically, defendants failed to disclose that: (1) there was an increasingly high risk that certain of Amarin's patents would be invalidated; (2) once invalidated, there was little to no chance of reversing that ruling; (3) the Company's litigation was preventing it from effectuating a successful takeover; and (4) defendants were downplaying the true threat the ongoing ANDA litigation posed to the Company's business and future prospects.

On March 30, 2020, Amarin announced that "the United States District Court for the District of Nevada's rul[ed] in favor of the generic companies in the company's patent litigation against two filer of abbreviated new drug applications, or ANDAs, for Amarin's VASCEPA® (icosapent ethyl) capsule franchise." On this news, Amarin's share price plummeted over 70.5% to close at $4.00 per share on March 31, 2020. Despite reassuring investors that the Company would ultimately prevail on the patent litigation, on June 21, 2021, investors learned "that the Supreme Court rejected the [C]ompany's bid to revive Vascepa patents." On this news, Amarin's share price fell 8.3%, to close at $4.54 on June 23, 2021.

If you purchased shares of Amarin Corporation plc (AMRN) between December 5, 2018 and June 21, 2021, you have until December 23, 2021, to ask the court to appoint you lead plaintiff for the class.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:

Aaron Dumas
(800) 350-6003
Shareholder Information Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Amarin Corporation plc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

View source version on


Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
(800) 350-6003

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting